Post-earnings recap
Reported
Wed, Nov 1, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
Corcept Therapeutics reported an earnings per share of $0.28, exceeding expectations significantly. However, there was no revenue data provided, which leaves some uncertainty. The stock reacted slightly positively, increasing by 0.04%, indicating a modest investor confidence following the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.28 | N/A | +29.63% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—